Inhibrx Biosciences, Inc. (INBX): Cash & Equivalents
$124.22M
As of 2025-12-31
$133.34M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $124.22M | -18.6% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $152.60M | -45.1% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $277.92M | n/a | 2025-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $124.22M | -18.6% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.66M | -15.4% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $8.08M | -45.9% |
| Pluri Inc. (PLUR) | 2026-06-30 | $3.53M | -40.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
Compare INBX, SCNI, OTLK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗